US Pharma MarketingThe post Health Canada authorises Dexcom G7 15 Day CGM appeared first on Medical Device Network.
Health Canada authorises Dexcom G7 15 Day CGM
Health Canada has granted authorisation for the Dexcom G7 15 Day continuous CGM for adults aged 18 years and above with diabetes. The device demonstrates a MARD of 8% and includes a 12-hour grace period and mobile app compatibility. The Dexcom G7 features waterproofing and direct connectivity to Apple Watch. Credit: Dexcom / Business Wire. Health Canada has granted authorisation for the Dexcom G7 15 Day continuous glucose monitor (CGM) for adults aged 18 years and older with diabetes. Offering 15.5 days of wear, the device supplies real-time glucose data. It is intended to support ongoing glucose management. Combine business…
Health Canada has granted authorisation for the Dexcom G7 15 Day continuous CGM for adults aged 18 years and above with diabetes.
Source: Medical Device Network